Our phase I trial showed that the recombinant human Hsp110-gp100 chaperone vaccine could activate CD8+ T cells in patients with advanced, pretreated melanoma [16], which supports therapeutic applications using these antigen-targeted chaperone complex vaccines to generate and/or expand tumor-reactive T cells for cancer eradication. Here, HSPH1 is linked to neoplasm.